7. Wang XM, Guo LC, Xue SL, et al. Pulmonary mucormycosis: a case report and review of the literature. Oncol Lett, 2016, 11(5): 3049-3053.
[5]
8. Walsh TJ, Gamaletsou MN, McGinnis MR, et al. Early clinical and laboratory diagnosis of invasive pulmonary, extrapulmonary, and disseminated mucormycosis (zygomycosis). Clin Infect Dis, 2012, 54 Suppl 1: S55-s60.
[6]
9. Vaezi A, Moazeni M, Rahimi MT, et al. Mucormycosis in Iran: a systematic review. Mycoses, 2016, 59(7): 402-415.
[7]
10. Dube P, Saroa R, Palta S. Coinfection in intensive care unit with pulmonary tuberculosis and mucormycosis: a clinical dilemma. Indian J Crit Care Med, 2016, 20(3): 191-193.
[8]
11. Danion F, Aguilar C, Catherinot E, et al. Mucormycosis: new developments into a persistently devastating infection. Semin Respir Crit Care Med, 2015, 36(5): 692-705.
[9]
12. McAdams HP, Rosado de Christenson M, Strollo DC, et al. Pulmonary mucormycosis: radiologic findings in 32 cases. Am J Roentgenol, 1997, 168(6): 1541-1548.
[10]
13. Jung J, Kim MY, Lee HJ, et al. Comparison of computed tomographic findings in pulmonary mucormycosis and invasive pulmonary aspergillosis. Clin Microbiol Infect, 2015, 21(7): 684.
[11]
14. Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guide lines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect, 2014, 20 Suppl 3: 5-26.
[12]
16. Ville S, Talarmin JP, Gaultier-Lintia A, et al. Disseminated mucormycosis with cerebral involvement owing to rhizopus microsporus in a kidney recipient treated with combined liposomal amphotericin B and posaconazole therapy. Exp Clin Transplant, 2016, 14(1): 96-99.
[13]
17. Kim JH, Williams K. Posaconazole salvage treatment for invasive fungal infection. Mycopathologia, 2014, 178(3-4): 259-265.
[14]
18. Astellas: FDA Advisory Committee Briefing Document: Isavuconium - Invasive Aspergillosis and Invasive Mucormycosis. Available from: http://www.fda.gov/downloads.
[15]
19. Graves B, Morrissey CO, Wei A, et al. Isavuconazole as salvage therapy for mucormycosis. Med Mycol Case Rep, 2016, 11: 36-39.
[16]
22. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis, 2008, 47(4): 503-509.
15. Chitasombat MN, Kontoyiannis DP. Treatment of mucormycosis in transplant patients: role of surgery and of old and new antifungal agents. Curr Opin Infect Dis, 2016, 29(4): 340-345.
[21]
20. Miceli MH, Kauffman CA. A new broad-spectrum triazole antifungal agent. Clin Infect Dis, 2015, 61(10): 1558-1565.
[22]
21. Afolayan O, Copeland H, Hargrove R, et al. Successful treatment of invasive pulmonary mucormycosis in an immunocompromised patient. Ann Thorac Surg, 2016, 101(4): e117-e119.
